FLT4 Protein (His tag)

Catalog No. ABIN7195831

Product Details

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: HEK-293 Cells

Purification tag / Conjugate: This FLT4 protein is labelled with His tag.

Purpose: Recombinant Mouse VEGFR3/FLT4 Protein (His Tag)(Active)

Sequence: Met 1-Glu 775

Characteristics: A DNA sequence encoding the mouse FLT4 (P35917-1) extracellular domain (Met 1-Glu 775) was expressed, with a polyhistidine tag at the C-terminus.

Purity: > 97 % as determined by SDS-PAGE

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: 1. Measured by its binding ability in a functional ELISA.2. Immobilized mouse VEGFR3-His at 10 μg/mL (100 μl/well) can bind mouse Fc-VEGFD, The EC50 of mouse Fc-VEGFD is 44 ng/mL.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Alternative Name: VEGFR3/FLT4 (FLT4 Products)

Synonyms: FLT41 Protein, LMPH1A Protein, PCL Protein, VEGFR3 Protein, AI323512 Protein, Chy Protein, Flt-4 Protein, VEGFR-3 Protein, Vegfr3 Protein, cb1059 Protein, fms related tyrosine kinase 4 Protein, FMS-like tyrosine kinase 4 Protein, fms-related tyrosine kinase 4 Protein, FLT4 Protein, Flt4 Protein, flt4 Protein

Background:

Background: Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Synonym: AI323512;Chy;Flt-4;VEGFR-3;VEGFR3

Molecular Weight: 86.4 kDa

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling